广州中医药大学第二临床医学院,广东省广州市越秀区大德路111号,510120
maoshuai@gzucm.edu.cn
收稿:2023-04-02,
修回:2023-08-20,
纸质出版:2023-10-17
移动端阅览
郑舒馨,于玲,招煦杰等.通冠胶囊对急性ST段抬高型心肌梗死患者左心室重构及肠道菌群的影响——一项随机对照临床研究[J].中医杂志,2023,64(20):2090-2100.
ZHENG Shuxin,YU Ling,ZHAO Xujie,et al.Effects of Tongguan Capsules (通冠胶囊)on Left Ventricular Remodeling and Gut Microbiota in Patients with Acute ST-segment Elevation Myocardial Infarction: A Randomized Controlled Clinical Study[J].Journal of Traditional Chinese Medicine,2023,64(20):2090-2100.
郑舒馨,于玲,招煦杰等.通冠胶囊对急性ST段抬高型心肌梗死患者左心室重构及肠道菌群的影响——一项随机对照临床研究[J].中医杂志,2023,64(20):2090-2100. DOI: 10.13288/j.11-2166/r.2023.20.009.
ZHENG Shuxin,YU Ling,ZHAO Xujie,et al.Effects of Tongguan Capsules (通冠胶囊)on Left Ventricular Remodeling and Gut Microbiota in Patients with Acute ST-segment Elevation Myocardial Infarction: A Randomized Controlled Clinical Study[J].Journal of Traditional Chinese Medicine,2023,64(20):2090-2100. DOI: 10.13288/j.11-2166/r.2023.20.009.
目的
2
观察通冠胶囊对急性心肌梗死后患者心室重构的疗效及安全性,并探讨可能的作用机制。
方法
2
收集急性ST段抬高型心肌梗死患者53例,随机分为治疗组26例和对照组27例。两组患者均行急诊经皮冠状动脉介入治疗术(PCI)后当日,对照组予以西医标准治疗方案,治疗组则在西医标准治疗方案基础上加用通冠胶囊(每次4.5 g,每日3次)口服,两组疗程均为12周。收集两组治疗前后患者超声心动图数据和粪便样本,测量计算左室射血分数(LVEF)、左室舒张末期容积指数(LVEDVi)、左室收缩末期容积指数(LVESVi)、左室质量指数(LVMi),比较两组左心室重构例数;同时对粪便样本采用16S rDNA测序,分析肠道菌群多样性、菌群组成、组间差异菌群;记录研究期间两组患者主要不良心血管事件(MACEs)发生率及不良反应;将两组患者治疗后菌群数据与LVEF、LVEDVi、LVESVi、LVM、LVMi进行Spearman相关性分析。
结果
2
本研究治疗组脱落1例,对照组脱落2例,两组最终纳入分析各25例。对照组治疗后LVEDVi、LVESVi、LVMi均高于本组治疗前(
P
<0.05);治疗后治疗组LVEDVi、LVESVi、LVMi均低于对照组(
P
<0.05)。治疗组左室重构发生5例(20.00%),对照组发生13例(52.00%),治疗组左心室重构发生率低于对照组(
P
=0.03)。治疗组治疗后较本组治疗前、对照组治疗后菌群丰度ACE估计量、Chao估计量均升高(
P
<0.05)。治疗组治疗后拟杆菌门较治疗前增多,厚壁菌门、变形菌门、髌骨菌门较治疗后减少(
P
<0.05)。治疗后组间比较,治疗组拟杆菌门较对照组明显增多,普雷沃菌属、琼脂杆菌属、小杆菌属、真杆菌属相对丰度上调,肠球菌属相对丰度下调(
P
<0.05或
P
<0.01)。治疗期间两组MACEs发生率及不良反应发生情况比较差异无统计学意义(
P
>0.05)。相关性分析结果显示,普雷沃菌属与LVEF呈正相关,与LVEDVi、LVESVi、LVM、LVMi呈负相关(
P
<0.01);琼脂杆菌属与LVEDVi、LVESVi呈负相关(
P
<0.01);肠球菌属与LVESVi呈正相关(
P
<0.05)。
结论
2
通冠胶囊可改善急性ST段抬高型心肌梗死患者心室重构,且安全性较好;其机制可能与调整肠道普雷沃菌属、琼脂杆菌属、小杆菌属、肠球菌属等相关菌属的富集,增加有益菌定植和菌群多样性,调整肠道菌群结构有关。
Objective
2
To observe the efficacy and safety of
Tongguan Capsule
(通冠胶囊)on ventricular remodeling in patients after acute myocardial infarction (AMI), and to explore the possible mechanism.
Methods
2
A total of 53 ST-segment elevation myocardial infarction (STEMI) patients were collected and randomly divided into 26 cases in the treatment group and 27 cases in the control group. The control group was given conventional therapy after percutaneous coronary intervention (PCI) for AMI, and the treatment group was given
Tongguan Capsules
(4.5 g each time, 3 times a day) on the basis of the control group. The course of treatment was 12 weeks. Echocardiographic data and stool samples were collected from subjects before and after the intervention, and left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume index (LVEDVi), left ventricular end-systolic volume index (LVESVi), left ventricular mass index (LVMi) were measured and calculated, so as to compare the number of cases of left ventricular remodeling in the two groups. At the same time, 16S rDNA sequencing was performed on the stool samples to analyze the diversity of gut microbiota (GM), the composition of the GM, the GM difference between the groups; recording the incidence of major adverse cardiovascular events (MACEs) and adverse reactions of patients in the two groups during the study period; and performing Spearman's correlation analyses of the post-treatment flora data with LVEF, LVEDVi, LVESVi, LVM, and LVMi in the two groups.
Results
2
One case fail to follow up in the treatment group and 2 cases fail to follow up in the control group, and 25 cases in each of the two groups were finally included in the analysis. LVEDVi, LVESVi, and LVMi of the control group after treatment were higher than those before treatment (
P
<0.05); after treatment, LVEDVi, LVESVi and LVMi in the treatment group were lower than those in the control group (
P
<0.05). Left ventricular remodeling occurred in 5 cases (20.00%) in the treatment group and 13 cases (52.00%) in the control group, and the incidence of left ventricular remodeling in the treatment group was lower than that in the control group (
P
=0.03). After treatment, the ACE estimation and Chao estimation of bacterial abundance in the treatment group were higher than that before treatment and that in the control group (
P
<0.05). The treatment group showed an increase in Mycobacterium anisopliae phylum and a decrease in Mycobacterium thickum, Mycobacterium anisopliae phylum, and Mycobacterium patella phylum after treatment (
P
<0.05). When comparing between groups after treatment, the relative abundance of Prevotella, Agathobacter, Dialister, Eubacterium coprostanoligenes group was up-reuglated and the relative abundance of Enterococcus was down-regulated in the treatment group(
P
<0.05 or
P
<0.01). There was no statistically significant difference in the incidence of MACEs and the occurrence of adverse reactions between groups during treatment (
P
>0.05). The results of correlation analysis showed that Prevotella were positively correlated with LVEF and negatively correlated with LVEDVi, LVESVi, LVM, and LVMi (
P
<0.01). Agathobacter group were negatively correlated with LVEDVi, LVESVi (
P
<0.01); Enterococcus group were positively correlated with LVESVi (
P
<0.05).
Conclusion
2
Tongguan Capsules
can improve ventricular remodeling in patients with acute ST-segment elevation myocardial infarction with better safety; its mechanism may be related to adjusting the enrichment of related bacteria such as Prevotella, Dialister and Enterococcus and other related bacterial genera, increasing the colonization and diversity of beneficial bacteria, and adjusting the structure of GM.
国家心血管病中心 . 《中国心血管健康与疾病报告2021》概述 [J]. 中国心血管病研究 , 2022 , 20 ( 7 ): 577 - 596 .
RODRIGUEZ-PALOMARES JF , GAVARA J , FERREIRA-GONZÁLEZ I , et al . Prognostic value of initial left ventricular remodeling in patients with reperfused STEMI [J]. JACC Cardiovasc Imaging , 2019 , 12 ( 12 ): 2445 - 2456 .
SÁNCHEZ B , DELGADO S , BLANCO-MÍGUEZ A , et al . Probiotics, gut microbiota, and their influence on host health and disease [J]. Mol Nutr Food Res , 2017 , 61 ( 1 ). doi: 10.1002/mnfr.201600240 http://dx.doi.org/10.1002/mnfr.201600240 .
WU ZX , LI SF , CHEN H , et al . The changes of gut microbiota after acute myocardial infarction in rats [J]. PLoS One , 2017 , 12 ( 7 ): e0180717 .
MAO S , OUYANG W , ZHOU Y , et al . Addition of Chinese herbal remedy, Tongguan Capsules, to the standard treatment in patients with myocardial infarction improve the ventricular reperfusion and remodeling: Proteomic analysis of possible signaling pathways [J]. J Ethnopharmacol , 2020 , 257 : 112794 . doi: 10.1016/j.jep. 2020. 112794 http://dx.doi.org/10.1016/j.jep.2020.112794 .
KAMO T , AKAZAWA H , SUZUKI JI , et al . Novel concept of a Heart-Gut Axis in the pathophysiology of heart failure [J]. Korean Circ J , 2017 , 47 ( 5 ) : 663 - 669 .
中华医学会心血管病学分会 , 中华心血管病杂志编辑委员会 . 急性ST段抬高型心肌梗死诊断和治疗指南(2019) [J]. 中华心血管病杂志 , 2019 , 47 ( 10 ): 766 - 783 .
中国医师协会中西医结合医师分会 , 中国中西医结合学会心血管病专业委员会 , 中国中西医结合学会重症医学专业委员会 , 等 . 急性心肌梗死中西医结合诊疗专家共识 [J]. 中国中西医结合杂志 , 2014 , 34 ( 4 ): 389 - 395 .
郭志情 . CHA2DS2-VASc-HSF评分对冠状动脉旋磨术中慢血流的预测价值 [D]. 合肥 : 安徽医科大学 , 2023 .
刘泉颖 . 通冠胶囊对急性心肌梗死患者介入术后心功能及生活质量影响的研究 [D]. 广州 : 广州中医药大学 , 2010 .
沙玛曲卓 , 王丽娟 . 双平面Simpson法对冠心病患者PCI治疗前后左心室容积及收缩功能的评估价值 [J]. 川北医学院学报 , 2022 , 37 ( 5 ): 653 - 656 .
张经伟 , 邹玉兰 . 人体体表面积测量公式计算法与手掌法的比较研究 [J]. 法医学杂志 , 2000 , 16 ( 2 ): 102 - 103 .
COKKINOS DV , BELOGIANNEAS C . Left ventricular remodelling: a problem in search of solutions [J]. Eur Cardiol , 2016 , 11 ( 1 ): 29 - 35 .
MCCRACKEN VJ , SIMPSON JM , MACKIE RI , et al . Molecular ecological analysis of dietary and antibiotic-induced alterations of the mouse intestinal microbiota [J]. J Nutr , 2001 , 131 ( 6 ): 1862 - 1870 .
GULATI M , LEVY PD , MUKHERJEE D , et al . 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice guidelines [J]. Circulation , 2021 , 144 ( 22 ): e368 - e454 .
陈伯钧 , 苏学旭 , 孟丽琴 , 等 . 通冠胶囊对急性心肌梗塞大鼠心室重构的影响 [J]. 时珍国医国药 , 2009 , 20 ( 3 ): 524 - 526 .
QI J , YU J , WANG L , et al . Tongguan capsule protects against myocardial ischemia and reperfusion injury in mice [J]. Evid Based Complement Alternat Med , 2013 , 45 ( 5 ): e23 .
张军 , 招煦杰 , 杨澄 , 等 . 通冠胶囊后适应对大鼠心肌缺血再灌注损伤的保护作用及机制的研究 [J]. 临床合理用药杂志 , 2011 , 4 ( 32 ): 11 - 12 .
SHANAHAN F . Probiotics in perspective [J]. Gastroenterology , 2010 , 139 ( 6 ): 1808 - 1812 .
CUI L , ZHAO T , HU H , et al . Association study of gut flora in coronary heart disease through high-throughput sequencing [J]. Biomed Res Int , 2017 , 2017 : 3796359 . doi: 10.1155/2017/3796359 http://dx.doi.org/10.1155/2017/3796359 .
蔡昭玲 . 慢性心力衰竭患者肠道微生物菌群及其血清代谢组学研究 [D]. 福州 : 福建医科大学 , 2021 .
SHIN NR , WHON TW , BAE JW . Proteobacteria: microbial signature of dysbiosis in gut microbiota [J]. Trends Biotechnol , 2015 , 33 ( 9 ): 496 - 503 .
SUN W , DU D , FU T , et al . Alterations of the gut microbiota in patients with severe chronic heart failure [J]. Front Microbiol , 2022 , 12 : 813289 . doi: 10.3389/fmicb.2021.813289 http://dx.doi.org/10.3389/fmicb.2021.813289 .
CHAMBERS ES , VIARDOT A , PSICHAS A , et al . Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults [J]. Gut , 2015 , 64 ( 11 ): 1744 - 1754 .
BORGO F , VERDUCI E , RIVA A , et al . Relative abundance in bacterial and fungal gut microbes in obese children: a case control study [J]. Child Obes , 2017 , 13 ( 1 ): 78 - 84 .
HAN Y , GONG Z , SUN G , et al . Dysbiosis of gut microbiota in patients with acute myocardial infarction [J]. Front Microbiol , 2021 , 12 : 680101 . doi: 10.3389/fmicb. 2021.680101 http://dx.doi.org/10.3389/fmicb.2021.680101 .
张敏州 , 杨广 , 韩凌 . 通冠胶囊的急性毒理实验 [J]. 中西医结合心脑血管病杂志 , 2006 , 4 ( 9 ): 787 .
0
浏览量
3
下载量
2
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号